Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series

Fischbach, Wolfgang; Me, Goebeler-Kolve; Dragosics, B; Greiner, Andreas; Stolte, Manfred

doi:10.1136/gut.53.1.34

Cited by 313 publications

(227 citation statements)

References 33 publications

Supporting

Mentioning

193

Contrasting

Unclassified

Order By: Relevance

“…The disease recurrence rate has been reported to vary from 7% to 12.5% in patients who once achieved CR. 8,10,14,15 The rate of disease recurrence in our study (4 of 62 patients [6.5%]) was similar to that reported by Savio et al 10 (5 of 71 patients [7.0%]) and by Fischbach et al 15 (4 of 56 patients [7.1%]). In the absence of the H. pylori reinfection or the DLBL component, such a histologic relapse is frequently a transient self-limiting event, as observed in our study and some previous reports.…”

Section: Discussionsupporting

confidence: 78%

“…To our knowledge, there have been only 2 large series from Germany that have investigated Ͼ 80 patients (n ϭ 120 and n ϭ 90) for median follow-up periods of Ͼ 3 years. 14,15 The current study was the second largest series (n ϭ 96) with a long-term follow-up period (median, 38 months). We demonstrated favorable prognosis as determined by OS and EFS in 96 patients with gastric MALT lymphoma after eradication therapy (Fig.…”

Section: Discussionmentioning

confidence: 99%

“…[5][6][7][8][9][10][11][12][13][14][15] Nowadays, eradication therapy has become the first choice of treatment for this disease. However, the number of long-term follow-up studies after H. pylori eradication therapy comprising a large cohort of patients with gastric MALT lymphoma is still insufficient.…”

Section: Discussionmentioning

confidence: 99%

“…6 -13 However, there were few patients in the previous series, and data on the long-term follow-up after eradication therapy are rare. 14,15 Conversely, the therapeutic strategy for gastric MALT lymphoma that does not respond to H. pylori eradication therapy still remains to be elucidated. In the past, the majority of such patients tended to be treated by surgical resection.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

Nakamura

Matsumoto

Suekane

et al. 2005

Cancer

View full text Add to dashboard Cite

BACKGROUNDThe goals of the current study were to elucidate the long‐term outcome of Helicobacter pylori eradication therapy for gastric mucosa‐associated lymphoid tissue (MALT) lymphoma and to clarify the therapeutic efficacy of stomach‐conserving treatments for patients not responding to eradication therapy.METHODSNinety‐six patients with gastric MALT lymphoma, including 17 patients with areas of diffuse large B‐cell lymphoma, were treated by H. pylori eradication. Patients not responding to eradication therapy underwent either a gastrectomy, multiagent chemotherapy, oral monochemotherapy (OMC), or radiotherapy (RT). Predictive factors for the response to eradication therapy, overall survival (OS), and event‐free survival (EFS) were determined by the Kaplan–Meier analysis with the log‐rank test. The efficacy of second‐line treatment was compared between OMC and RT.RESULTSAfter eradication therapy, 62 (65%) patients achieved complete disease remission (CR). Transient histologic disease recurrence was confirmed in 4 (6.5%) of 62 patients with CR during the follow‐up (median, 37.5 months). The OS and EFS probabilities after 5 years were 0.96 and 0.80, respectively. Second‐line treatment was performed in 31 patients; gastrectomy in 4 patients, multiagent chemotherapy in 5 patients, OMC in 12 patients, and RT in 10 patients. There were no differences in the CR rate, OS, EFS, or toxicity between the OMC and RT groups.CONCLUSIONSH. pylori eradication therapy was an effective first‐line treatment for patients with gastric MALT lymphoma, which led to a favorable long‐term outcome. OMC and RT had an equivalent efficacy as a second‐line treatment in nonresponding patients to eradication therapy. Cancer 2005. © 2005 American Cancer Society.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

Nakamura

Matsumoto

Suekane

et al. 2005

Cancer

View full text Add to dashboard Cite

show abstract

“…Relapse of gastric MALT lymphoma was recorded in 64 of the 852 patients who achieved CR (7.5%), and treatment failure (relapse, PD, and/or non‐CR at ≥6 months after successful H. pylori eradication) was observed in 144 of all 1055 patients (13.6%). Table 3 summarizes 8 prospective studies,17, 18, 19, 30, 31, 32, 33 including the present investigation, of 47‐120 patients. The present study (n = 97) represents the third largest among these prospective studies.…”

Section: Discussionmentioning

confidence: 99%

Anti‐Helicobacter pylori therapy in localized gastric mucosa‐associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan

et al. 2018

View full text Add to dashboard Cite

Background Helicobacter pylori eradication therapy was approved in Japan for the first‐line, standard treatment of H. pylori‐positive gastric mucosa‐associated lymphoid tissue (MALT) lymphoma. Although several retrospective studies or small‐scale single‐center studies have been reported, a prospective, large‐scale, nationwide, multicenter study has not been reported from Japan.Materials and MethodsWe conducted a prospective, nationwide, multicenter study to evaluate the clinical efficacy of rabeprazole‐based triple H. pylori eradication therapy for patients with localized gastric MALT lymphoma in practice‐based clinical trial. A total of 108 H. pylori‐positive patients with stage I/II 1 gastric MALT lymphoma underwent H. pylori eradication therapy. The primary endpoints were complete remission (CR) rate and the rate of transfer to secondary treatment. The secondary endpoints were CR maintenance duration and overall survival (OS).Results CR of lymphoma was achieved in 84 of 97 patients (86.6%), during the period 2.0‐44.7 months (median, 5.3 months) after starting H. pylori eradication treatment. CR was maintained in 77 of 81 patients (95.1%) for 0.4‐53.2 months (median, 33.1 months). Secondary treatments (radiotherapy, rituximab, or gastrectomy) for gastric MALT lymphoma were needed in 10 of the 97 patients (10.31%). During follow‐up, OS rate was 96.9% (94/97) and the causes of 3 deaths were not related to lymphoma.ConclusionsRabeprazole‐based H. pylori eradication therapy demonstrated a high CR rate, long CR maintenance, and a good OS for patients with localized gastric MALT lymphoma in this prospective, practice‐based, multicenter study.

show abstract

From Robert Koch to Bradford Hill

Margo¹

2011

Arch Ophthalmol

View full text Add to dashboard Cite

Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series

Cited by 313 publications

References 33 publications

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

Long‐term clinical outcome of Helicobacter pylori eradication for gastric mucosa‐associated lymphoid tissue lymphoma with a reference to second‐line treatment

Anti‐Helicobacter pylori therapy in localized gastric mucosa‐associated lymphoid tissue lymphoma: A prospective, nationwide, multicenter study in Japan

From Robert Koch to Bradford Hill

Contact Info

Product

Resources

About